Novan (NOVN) – PRNewswire
-
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis
-
New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies
-
FDA approves Xolair® (omalizumab) as first and only medicine for children and adults with one or more food allergies
-
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
-
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
-
Novartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
-
FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases
-
Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
-
Novartis strengthens commitment to Beacon of Hope initiative, engages new collaborators to support clinical trial diversity, break down economic and education barriers
-
US FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease
-
Novartis premieres powerful new docuseries at Tribeca Festival to shine a light on debilitating skin disease
-
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA
-
Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
-
Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
-
Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5
-
Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH
-
Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
-
Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (SB206) in Patients with Molluscum Contagiosum in JAMA Dermatology
-
EVENING POST GROUP SELLS EPI HEALTH TO NOVAN, INC
-
Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i
-
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
-
Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events
-
NAO SAM investment fund reports a return of more than 25 per cent in its first two years of operation
-
Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
-
Sosei Heptares Notes That Enerzair® Breezhaler® (QVM149) has been Recommended for Approval in the European Union for Treating Uncontrolled Asthma
-
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Back to NOVN Stock Lookup
